The observation that a tetravalent ligand induces powerful activation of CLEC-2 has clinical relevance in heparin-induced-thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia with thrombosis (VITT). This evidence concerns the gene CLEC1B and autoimmune thrombocytopenic purpura.